These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 10815892

  • 1. Phase I and pharmacological study of weekly administration of the polyamine synthesis inhibitor SAM 486A (CGP 48 664) in patients with solid tumors. European Organization for Research and Treatment of Cancer Early Clinical Studies Group.
    Eskens FA, Greim GA, van Zuylen C, Wolff I, Denis LJ, Planting AS, Muskiet FA, Wanders J, Barbet NC, Choi L, Capdeville R, Verweij J, Hanauske AR, Bruntsch U.
    Clin Cancer Res; 2000 May; 6(5):1736-43. PubMed ID: 10815892
    [Abstract] [Full Text] [Related]

  • 2. A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.
    Siu LL, Rowinsky EK, Hammond LA, Weiss GR, Hidalgo M, Clark GM, Moczygemba J, Choi L, Linnartz R, Barbet NC, Sklenar IT, Capdeville R, Gan G, Porter CW, Von Hoff DD, Eckhardt SG.
    Clin Cancer Res; 2002 Jul; 8(7):2157-66. PubMed ID: 12114416
    [Abstract] [Full Text] [Related]

  • 3. A phase I study of a new polyamine biosynthesis inhibitor, SAM486A, in cancer patients with solid tumours.
    Paridaens R, Uges DR, Barbet N, Choi L, Seeghers M, van der Graaf WT, Groen HJ, Dumez H, Buuren IV, Muskiet F, Capdeville R, Oosterom AT, de Vries EG.
    Br J Cancer; 2000 Sep; 83(5):594-601. PubMed ID: 10944598
    [Abstract] [Full Text] [Related]

  • 4. A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.
    Hurwitz HI, Cohen RB, McGovren JP, Hirawat S, Petros WP, Natsumeda Y, Yoshinari T.
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):139-47. PubMed ID: 16819636
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
    Trocòniz IF, Garrido MJ, Segura C, Cendrós JM, Principe P, Peraire C, Obach R.
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
    [Abstract] [Full Text] [Related]

  • 13. [The clinical phase I study of TNP-351. The TNP-351 Research Committee].
    Taguchi T, Niitani H, Furue H, Tsukagoshi S, Kanamaru R, Hasegawa K, Akazawa S, Yoneda S, Tominaga T, Sasaki T.
    Gan To Kagaku Ryoho; 1995 Feb; 22(2):259-71. PubMed ID: 7857102
    [Abstract] [Full Text] [Related]

  • 14. A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies.
    Faivre S, Raymond E, Boige V, Gatineau M, Buthaut X, Rixe O, Bernareggi A, Camboni G, Armand JP.
    Clin Cancer Res; 2001 Jan; 7(1):43-50. PubMed ID: 11205916
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer.
    Cunningham CC, Holmlund JT, Schiller JH, Geary RS, Kwoh TJ, Dorr A, Nemunaitis J.
    Clin Cancer Res; 2000 May; 6(5):1626-31. PubMed ID: 10815879
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.